Abstracts tagged "autoimmune diseases"

Abstract Number: 2304 • ACR Convergence 2024
Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye
Esen Akpek¹, Ian Saldanha², Pineal Bareamichael² and Michael Lin³, ¹Wilmer Eye Institute, JHU, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dry Eye Disease (DED) is a common multifactorial condition that significantly impacts patient quality of life. The etiology of DED is complex, involving tear…
Abstract Number: 2468 • ACR Convergence 2024
Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease
Cristina Padilla¹, Veena Katikineni², Yongseok Park¹, Leigh Freno³, Maureen Laffoon⁴ and Robyn Domsic⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Providence, Victorville, CA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is characterized as episodic color changes of the digits occurring with exposure to cold environments, sudden temperature decreases, and emotional stress. …
Abstract Number: 2612 • ACR Convergence 2024
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Ana Cristina Medeiros-Ribeiro¹, Joao de Oliveira², Nadia Aikawa³, Sandra Pasoto², Leonard Kupa², Carla Goncalves Schahin Saad⁴, Luciana Parente², ANA PAULA ASSAD², Eduardo Borba², Emily Figueiredo Neves Yuki², Andrea Shimabuco⁴, Karina Bonfiglioli², Diogo Domiciano², Percival Sampaio-Barros⁴, Andre Franco², Julio Moraes⁵, Murillo Dorio², Claudia Goldenstein-Schainberg², Henrique Carriço Da Silva², Lucas Guimarães², Fernanda Chaer⁶, Caio Laguna Reis de Carvalho², Henrique Dalmolin², Clovis Silva⁷ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
Abstract Number: 0081 • ACR Convergence 2024
The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses
Hillary Struthers¹, Kofi Asare-Konadu², Emily Vance¹ and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the entheses of the spine and/or sacroiliac joints. The cause of axSpA…
Abstract Number: 0186 • ACR Convergence 2024
Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
Ekemini Ogbu¹, Stela Florea², Donna Diorio², Somak Roy², Dhriti Sharma², Michael Henrickson², Patricia Vega-Fernandez², Angela Migowa³, Sarangarajan Ranganathan² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³AGA KHAN UNIVERSITY, Nairobi, Kenya
Background/Purpose: Timely diagnosis of children and young adults with rheumatologic disorders remains a global challenge especially in lower-resource settings. There is limited access to diagnostic…
Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 0433 • ACR Convergence 2024
Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
Eleonora Giacobbe¹, Maria Chiara Gerardi², Clizia Gagliardi², Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Milan, Lombardia, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Takehiro HIrayama¹, Kohei Tsujimoto², Kayoko Kaneko³, Sakiko Isojima⁴, Kunihiro Ichinose⁵, Yasunori Iwata⁶, Kenji Oku⁷, Kenei Sada⁸, Yoshiya Tanaka⁹, Ayako Nakajima¹⁰, Keishi Fujio¹¹, Masakazu Matsushita¹², Takako Miyamae¹³, Atsuko Murashima³ and Atsushi Kumanogoh¹⁴, ¹Osaka university, Ibaraki City, Japan, ²Osaka University, Toyonaka, Osaka, Osaka, Japan, ³National Center for Child Health and Development, Setagaya, Tokyo, Japan, ⁴Showa Univeristy, Shinagawa, Tokyo, Japan, ⁵Shimane University, Izumo, Shimane, Japan, ⁶Kanazawa University, kanazawa, Japan, ⁷Kitazato University, Sagamihara, Kanagawa, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ¹¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., TOKYO, Japan, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Osaka University, Osaka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…
Abstract Number: 0830 • ACR Convergence 2024
Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells
Kevin Gao¹, Kristy Chiang¹, Sharon Subramanian¹, Xihui Yin², Paul Utz³, Kerstin Nundel¹, Katherine A. Fitzgerald⁴ and Ann Marshak-Rothstein¹, ¹UMass Chan Medical School, Worcester, MA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴UMass Chan Medical School, Worchester, MA
Background/Purpose: Gain-of-function mutations in STING, a critical mediator of dsDNA sensing, lead to a severe autoinflammatory syndrome known as STING-Associated Vasculopathy with onset in Infancy…
Abstract Number: 0902 • ACR Convergence 2024
Novel Role of TYK2mechanism in SLE Pathogenesis via T Cell and B Cell Pathways
Joshua Hoffman¹, Nicole Narayan² and Mera Tilley¹, ¹Alumis Inc, South San Francisco, CA, ²Alumis, South San Francisco, CA
Background/Purpose: SLE is a complex disease in need of novel therapies. Previously reported genome-wide association studies (GWAS) have identified a strong association between SLE and…
Abstract Number: 0977 • ACR Convergence 2024
Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Emily Rayens¹, Lina Sy¹, Lei Qian¹, Jun Wu¹, Bradley Ackerson¹, Yi Luo¹, Yanjun Cheng¹, Antony Lin¹, Zendi Solano¹, Justine De Jesus¹, Britta Amundsen¹, Ana Florea¹, Jen Ku¹, Elizabeth Chmielewski-Yee², Driss Oraichi², Harry Seifert², Huifeng Yun² and Hung-Fu Tseng¹, ¹Kaiser Permanente Southern California, Pasadena, CA, ²GSK, Rockville, MD
Background/Purpose: Individuals with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population. This interim analysis evaluated the vaccine…
Abstract Number: 1138 • ACR Convergence 2024
Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec
Mareva geslin¹, Julien Vachon², Naizhuo Zhao³, Elhadji Anassour Laouan Sidi², Sonia Jean⁴, audrey smargiassi² and Sasha Bernatsky⁵, ¹Universite de Montreal, Montreal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Institut national de santé publique du Québec, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Exposure to fine particles (PM2.5) has been associated with numerous health effects including with autoimmune rheumatic diseases (SARDs). While PM2.5 are composed of various…
Abstract Number: 1417 • ACR Convergence 2024
Organ-Specific Autoimmune Involvement in Primary Sjögren’s Disease
Gabriela Hernández-Molina and Ariel Garcia-Torralba, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: To assess the presence of organ-specific autoimmune diseases in a cohort of patients with primary Sjögren’s Disease (SjD).Methods: We retrospectively reviewed the records of…
Abstract Number: 1580 • ACR Convergence 2024
Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
Irene Carrión-Barberà¹, Laura Tío², Laura Triginer², María Lee², Alfredo Guillén-del Castillo³, Anna Ribes², Lidia Valencia Muntalà⁴, Jordi Monfort¹, Tarek Carlos Salman Monte:⁵, Carmen PIlar Simeón-Aznar³, Anna Pros¹ and Javier Narvaez-García⁶, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar Research Institute, Barcelona, Spain, ³Hospital Vall d'Hebron, Barcelona, Spain, ⁴Hospital de Bellvitge, Barcelona, Spain, ⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Overt PolyA (the clinical coexistence of ≥2 autoimmune diseases (AID) that fulfill classification criteria), is a frequent phenomenon in systemic sclerosis (SSc). However, the…
Abstract Number: 1726 • ACR Convergence 2024
Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study
Kathleen Vanni¹, Kaitlin McCarter¹, Xiaosong Wang², Caitlyn Duffy³, Jamie Dela Cruz³, Holly Wobma⁴, Sarah Nikiforow³, Elena Massarotti¹, Karen Costenbader⁵, Jessica Little¹, Ellen Gravallese⁶, Gregory McDermott⁷, Caron Jacobson³ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: CD19-targeted chimeric antigen receptor (CAR) T cell therapy is FDA-approved to treat lymphoma. A recent prospective case series of CD19 CAR T cell therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].